Pregled bibliografske jedinice broj: 15665
Platelet activities and thromboxane synthesis during external insulin pump treatment
Platelet activities and thromboxane synthesis during external insulin pump treatment // Abstracts of the 32nd annual meeting of the European association for the study of diabetes / Ferrannini, E. (ur.).
Beč: Springer, 1996. str. A238-A238 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 15665 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Platelet activities and thromboxane synthesis during external insulin pump treatment
Autori
Turk, Zdenka ; Flego, Iris ; Kerum, Gorazd ; Metelko, Željko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the 32nd annual meeting of the European association for the study of diabetes
/ Ferrannini, E. - Beč : Springer, 1996, A238-A238
Skup
32nd annual meeting of the European association for the study of diabetes
Mjesto i datum
Beč, Austrija, 01.09.1996. - 05.09.1996
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Diabetes; Platelets; Thromboxane synthesis
Sažetak
The effect of metabolic control on platelet activities was studied in 11 IDDM patients during 6 months of continuous subcutaneous insulin infusion (CSII) treatment in comparison to 3 months of conventional therapy. Patients chosen for the study were free of microvascular disease. The effectiveness of intensive therapy in lowering blood glucose was reflected in a significant HbA1c reduction (8.26ą1.78 vs 6.16ą0.46% ,p<0.001). The accompanying improvement in ex vivo aggregation of platelets in response to two doses of agonists was only observed with the achievement of glycemia control (ADP: 20.84ą4.61 vs 14.84ą3.03%, p<0.001; arachidonic acid: 22.04ą4.26 vs 16.0ą3.15%, p<0.01). The synthesis of thromboxane-B2, as a response to arachidonate, was lower during the CSII period (TxB2:415ą51 vs 382ą46 mg/lx106 plts), but with no statistical significance. Inspite of the fact that in all patients, lipoproteins were of normal values both before and after intensified therapy (HDL-c: 1.48ą0.5 vs 1.52ą0.4 mmol/l, NS; LDL-c:3.2ą1.3 vs 2.78ą1.0 mmol/l,NS), a significant correlation was observed between the atherogenic lipoproteins and proaggregatory thromboxane B2. Thus, in all patients, LDL-cholesterol before and during CSII showed a significant correlation with TXB2 generation (r=0.75,p<0.001), whereas at the same time its correlation with the corresponding values of HDL-cholesterol (r=-0.77, p<0.001) was negative. Along with normal fibrinogen level pre- and post-CSII (346ą79 vs 307ą56 g/l) we found a significant association between fibrinogen and ADP-induced aggregation in pretreatment period (r=0.63, p<0.03), but during CSII treatment this association was not observed. In the present study plasma fibrinogen significantly correlated with the level of glycemia (r=0.61,p<0.002).Results suggested that intensive insulin treatment reduced platelet aggregation in patients without microvascular disease when strict glycemia control was maintained and indicated that changes in platelet aggregation could directly result from changes in plasma glucose concentrations.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
045003
Ustanove:
Klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac